

Index

A

- AC6 transgenic studies, 156
- Adenylyl cyclase type 5 (AC5)
 - AC5 KO mice, longevity, 150
 - chronic catecholamine stimulation, 153
 - inhibition, 156
 - reduced oxidative stress, 153–156
- Aging
 - cancer, 417
 - cardiomyopathies, 150, 153
 - healthful, 148
 - oxidative stress, 148, 150
- Air pollution, 276
- Air, fossil-fuel products, 276
- Alpha-proteobacteria, 17, 18
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- Alzheimer's disease (AD)
 - A β and oxidative stress, 363–364
 - aging, CNS disorder, 362
 - aging, energy dysregulation, 103
 - aging, insulin receptors (IRs), 364
 - aging, memory processing, 300
 - aging, neurodegenerative diseases, 347
 - aging, neuronal dysfunction, 300
 - aging, oxidative stress (OS), 301–302
 - aging, progression, 301
 - aging, ROS management, 369
 - aging, tau and oxidative stress, 363
- Amyotrophic lateral sclerosis (ALS), 90
- Andes
 - antique population, 110
 - blood hemoglobin, 117
 - life at high altitude, 110
 - Peruvians, 114
- Angiotensin (Ang)
 - CaMKII inhibition, 197
 - cardioprotective effects, 196
 - immune cells and inflammation, 198
 - Na⁺-K⁺ pump, 197
- Antigen presenting cells, 432
- Antioxidant defense systems, 194
- Antioxidant enzymes, 30, 32
- Antioxidant supplementation
 - atherosclerosis and cardiovascular disease prevention, 202
 - biochemical profile, oxidative metabolism and stress, 201
 - cigarette smoking, 202
 - delaying aging, 202
 - elderly patients, 202
 - plasma levels, 200
 - vitamin E supplements, 202
- Antioxidants, 136
 - endogenous (*see* Endogenous antioxidants)
 - erythrocytes, 355
 - exogenous, 139–141
 - in humans, 354
- Apoptosis signal-regulating kinase 1 (ASK1), 168
- Aquaporins, 6
- AraA, FDA approved anti-viral drug, 157
- Arachidonic acid (AA) nitration, 80–82
- Arachidonyl (AA^{*}) radical, 80
- Arachidonylperoxyl (AAOO^{*}) radicals, 80
- Arachidonylperoxynitrites (AAOONO^{*})/nitrites, 80
- ASK1. *See* Apoptosis signal-regulating kinase 1 (ASK1)

- Atherosclerosis
 angioplasty-induced injury, 229
 diabetic/transplant vasculopathy, 229
 low blood flow model, 233
 restenosis, 230
- Atherosclerotic cardiovascular disease (ACVD), 200, 203
- Atmosphere evolution
 Archean era, 14
 carboniferous period, 15
 oxygen, 19, 20
 proterozoic era, 14
- Atrial fibrillation (AF), 198
- Autism Diagnostic (ADI-R) examination, 328
- Autism Diagnostic Generic (ADOS-G) examination, 328
- Autism spectrum disorders (ASD)
 autism description, 327
 autism diagnosis, 328
 autism environmental factors, 332
 autism genetic heritability, 328
 autism lymphocyte mitochondrial activities, 329
 autism, mitochondrial mutations, 331–332
 autism mtDNA, 328, 330
 autism oxidative phosphorylation, 328
 autism ROS, 329
- Autoxidation reactions, 51
- Axonal degeneration, 317, 318
 axonal H₂O₂, 317–318
 axonal actin cytoskeleton dynamics, 317, 318
 axonal molecular signaling, 317–318
 axonal production of ROS, 317
- A β and oxidative stress, 363–364
- B**
- Bacteria
 alpha-proteobacteria, 17, 18
 mitochondria, origin of, 17, 18
- Bi-specific T cell engager, 436
- Bligh and Dyer method, 82
- Brain aging. *See* Alzheimer's Disease (AD)
- Brain biomarkers
 in AD, PD and ALS, 351–352
 in CSF, 352
 histology, 350
 neuroimaging, 350
- C**
- Ca²⁺/calmodulin-dependent protein kinase II, 197
- Cambridge Heart Antioxidant Study (CHAOS), 157
- Cancer, 66, 411–416
 aging, 417
 cellular oxidative damage
 cellular responses, oxidative stress and ROS, 414–416
 DNA damage and mutation, 412
 DNA mutagenic lesions: 8-hydroxy-guanine, 412–414
 oxidative stress, 411
 intracolonic free radicals, 421
 metabolic pathways, 421
 mitochondrial dysfunction, 410–411, 420–421
 mtDNA homoplasmies and heteroplasmies, 417–418
 mtDNA mutations, 420
 mtDNA variations, 419–420
 S-nitrosylation, 165
 TNTs, 102–103
 Trx1-mediated nitrosylation, 171
- Carbohydrate metabolism, 7
- Cardiac dysfunction, 132, 134
 cardiac autonomic function, 278
 heart adverse effects, mechanisms, 278, 279
 IL-1 and IL-6, 279
 PMNL margination and microthrombi, 278
 pulmonary PM exposure, 278
- Cardiac ischemic syndromes, 246
- Cardiomyopathy, 150, 153, 157
- Cardiovascular diseases
 S-nitrosylation, 165
- Cell redox homeostasis, 194
- Cellular oxidative stress, 346
- Charcot-Marie-Tooth type 2A, 395
- CHARGE study, 328, 330
- Chronic mountain sickness, 114, 115
- Coenzyme Q10 deficiency, 377
- Complex I syndrome
 accessory subunit Ndufa11, 253
 ischemia/reperfusion, 253
 mitochondrial metabolism, 253, 254
 reversible S-glutathionylation, 253
- Copy number variants, 332
- Cuprizone-induced demyelination
 fission inhibition, 314
 lipid peroxidation, 314
- 3,5'-Cyclic guanosine monophosphate, 38, 40, 220
- Cytochrome *c* oxidase, 38

D

- Demyelinated axons
 - chronic CNS inflammation, 312
 - electrogenic machinery redistribution, 310
 - inflammatory products and free radicals, 311
 - mitochondria, 311
 - oligodendrocytes, 310
- Denitrosylation
 - caspases, 165
 - enzymatic, 165
 - GAPDH, 170
 - nitroso-redox balance, 169
 - non-enzymatic, 165
 - Trx1, 170
- Dynammin-related protein 1, 394, 395
- Dyslipidemia, 388

E

- Earth evolution
 - cenozoic, 16
 - mesozoic, 16
 - paleozoic, 15, 16
 - precambrian, 14
- Ebselen (2-phenyl-1,2-benzisoxaselenazol-3(2H)-one), 69
- EDRF. *See* Endothelial derived relaxing factor (EDRF)
- Endogenous antioxidants, 206
 - cardioprotection, I/R injury, 138
 - description, 136
 - oxidative stress, I/R, 136–138
- Endosymbiosis
 - alpha-proteobacteria, 18
 - endocytosis, 18
 - endosymbiont hypothesis, 17
- Endothelial derived relaxing factor (EDRF), 292
- Endothelial NOS (eNOS), 292
 - Ca²⁺-calmodulin-dependent enzyme, 292
 - L-NIO effect, 297
- Endothelin-1, 218
- eNOS. *See* Endothelial NOS (eNOS)
- Exogenous antioxidants in I/R, 139–141
- Extracellular-regulated kinase (ERK1/2), 397, 400

F

- Fenton reaction, 29
- Fetal imprinting, 334

G

- Gerschman theory, 33
- Glagov phenomenon, 229
- Glucose oxidation, 27

H

- Haber-Weiss reaction, 29
- Harman hypothesis, 33
- Healthful human aging
 - protection, oxidative stress, 147, 148
 - sympathetic stimulation, 148, 149
- Heart mitochondrial nitric oxide synthase
 - activity or expression, 41
 - Ca²⁺ concentration, 43
 - cardiomyocytes, 42
 - chronic hypoxia rats, 43
 - enalapril treatment, 42
 - isoform, 42
 - L-arginine concentration, 44
- Heteroplasmy, 417–418
- High altitude, life at, 112–115
 - blood hemoglobin, 117, 118
 - CMS (*see* Chronic mountain sickness (CMS))
 - erythropoiesis, 112
 - hypoxia, 112
 - oxidative stress
 - CYBA risk alleles, 113–114
 - excessive erythrocytosis, 113
 - hypoxemia, 112
 - reactive oxygen species, 113
 - Tibetans, 113
 - oxygen, lower availability, 112
 - physiological adaptations, hypoxia, 115, 116
 - ROS and RNOS, 112
- Himalayas
 - HA living, 110
 - Han ethnic group, 110, 114
 - hemoglobin levels, 111
- 8-HO-deoxyguanine, 417
- Homoplasmy, 417–418
- Hormesis, 221
- Human longevity
 - AC isoforms, 156
 - protection, oxidative stress, 147, 148
 - humoral pathway
 - blood transfusion, non-preconditioned animal, 262
 - blood-borne cardioprotective factors, 262
 - Langendorff system, 262
 - preconditioned animals, 262

- Hutchinson-Gilford progeria syndrome, 148
- Hydrogen hypothesis, 18
- Hydrogen peroxide (H_2O_2)
- cellular homeostasis and communication, 31
 - heart mitochondria, 39
 - mitochondrial production, 24–27
 - oxidative stress and redox signaling, 6
 - production by heart, 39
- Hydrophobic amino acids, 69
- Hydroxyl radical ($HO\bullet$)
- aging, 33
 - Fenton reaction, 29
 - H_2O_2 homolysis, 26
 - Haber-Weiss reaction, 29
 - half life, 31
 - oxygen toxicity, 24
 - phospholipid peroxidation, 27
 - radical generation, 27
 - steady state and half life, 29
- Hyperbaric oxygen, 24
- Hypercholesterolemia, 377, 378
- Hypertension, 199–201
- antioxidant supplementation
(*see* Antioxidant supplementation)
 - melatonin administration, 199
- Hypertriglyceridemia
- cell aging, 379
 - coenzyme Q10 deficiency, 377
 - CoQ₁₀ and α -tocopherol levels, 379
 - “pro-oxidant-to-antioxidants” plasma ratio,
377, 378
 - soft drinks consumption, 376
 - triglycerides, 379
- Hypoxia
- Andeans, 120
 - Ethiopians, 119
 - Han, 119
 - HIFs, 118
 - Tibetans, 118, 119
- I**
- Immune cells
- and inflammation, 197–198
- Immunotherapy, 430–436
- Inducible NOS (iNOS), 292
- Inflammation
- atherogenesis, 380
 - cytokines production, 86
 - denitrosylation, 171
 - etanercept attenuated, 198
 - and immune cells, 197–198
 - NO₂-AA, anti-inflammatory actions, 86–88
- Inflammatory bowel diseases, 64
- iNOS. *See* Inducible NOS (iNOS)
- Insulin receptors (IRs)
- AMPK and sirtuin1, 366
 - A β oligomers, 365
 - description, 364
 - GRB2 recruitment, 364
 - in CNS, 364
 - kinases, 366
 - medial hypothalamic neurons, 365
 - novel physiologic functions, 364
- Insulin resistance, 376, 381, 383–385,
388, 389
- Intercellular communication, 95
- cell-cell TNTs communication, 98–99
 - TNTs (*see* Tunneling nanotubes (TNTs))
- Intercellular transfer, 102
- nerve tissue cells, 102
 - TNTs (*see* Tunneling nanotubes (TNTs))
- Intermyofibrillar edema, 207
- Intracellular Ca²⁺-overload, I/R injury,
130, 132, 140
- Intracellular neurofibrillary tangles (NFTs)
- 4-hydroxynonenal (HNE), 363
 - intracellular deposits, PHFs, 363
- Iron and oxidative stress amplification, 313
- Iron porphyrins (FePs), 69
- IRs. *See* Insulin receptors (IRs)
- Ischemia/reperfusion (I/R) injury, 131–136, 138
- Ang, cardioprotective effects, 196
 - exogenous antioxidants, 139, 140
 - immune cells, 197
 - inflammatory condition, 197
 - insulin, 196
 - melatonin, 199
 - oxidative stress
 - Ca²⁺ levels, 132
 - DNA alterations, 134–135
 - endogenous antioxidants, 136, 138
 - lipid alterations, 133
 - mitochondria, 131, 132
 - molecular signaling pathways, 135–136
 - protein alterations, 133–134
 - stress and neutrophils, 198
 - α -tocopherol, 198
- Ischemic postconditioning (PostC), 182–184
- Ischemic preconditioning (PC), 178, 183, 184
- Isotope-coded affinity tag (ICAT) method, 169
- K**
- Kelch-like ECH-associating protein 1
(Keap1), 89
- Ketogenic diet (KGD)
- biological systems, 335

- gluten- and casein-free modified, 336
- in children, ASD symptoms, 336
- Kidney, 388
- cola drinking, 389
- hypertriglyceridemia
(*see* Hypertriglyceridemia)

L

- Leber's optic neuropathy, 246
- Left Ventricular Developed Pressure
(LVDP), 281
- Leydig tumor cells
 - androgens production, 392
 - MA-10, 398
 - mitochondria fusion, 396–398
- Lipid peroxidation, 24, 32, 103, 203–206
 - cardiolipin levels, 133
 - post-ischemic reperfusion
 - biochemical findings, human cardiac surgery, 203–205
 - histological findings, human cardiac surgery, 205–206
 - ROS and RNS, 133
 - subcellular distribution, 206
- Losartan, 195
- Lung cancer, 427, 431, 434, 437
- LVDP. *See* Left Ventricular Developed Pressure (LVDP)

M

- Macrophages, 312–313
- MALDI peptide mapping, 168
- Malonaldehyde, 32
- Manganese porphyrins, 67, 69
- Melanoma, 427, 430, 431, 433–437
- Melatonin, 199
- Membrane potential, 42, 44
- Mesenchymal stem cells, 100, 101
- Metabolic syndrome, 364–365, 376–379, 382–385
 - antioxidants, 367–368
 - antioxidant treatments, 368
 - atherosclerosis and arterial damage, 380–381
 - cardiorenal axis, 386–389
 - α -cell population, Langerhans islets
 - aspartame, 385
 - CoQ₁₀ in plasma, 382
 - nuclear immunolabeling, caspase-3 and PCNA, 384, 385
 - quantitative morphology and immunochemistry data, 383
 - α - and β -cells in pancreatic islets, 382

- β -cell population, Langerhans islets
 - HOMA-IR, 383
- characteristics, 376
- hypertriglyceridemia
 - “pro-oxidant-to-antioxidants” plasma ratio, 377, 378
 - cell aging, 379
 - coenzyme Q10 deficiency, 377
 - hypercholesterolemia, 377
 - CoQ₁₀ and α -tocopherol levels, 379
 - normoglycemia, 377
 - soft drinks consumption, 376
- insulin receptors (IRs), 364–366
- limbic brain structures, 364
- oxidative damage control, 368
- prebiotics and probiotics, 368
- risk factors, 364
- Metabolism
 - definition, 27
 - mitochondrial, O₂⁻ and H₂O₂, 26
 - mitochondrial, O₂⁻, H₂O₂, NO and ONOO⁻, 31
- Metalloporphyrins, 69
- Mfn2. *See* Mitofusin 2 (Mfn2)
- Microglia
 - OS, 312–313
- Mitochondria
 - cell physiology, 26–28
 - O₂⁻ and H₂O₂ production, 24–27
 - oxidative phosphorylation, 104
- Mitochondria-associated ER membranes, 394, 397, 401
- Mitochondrial and genomic mutations
 - genomic DNA (gDNA), 331
 - p53-signaling pathway, 332
 - PTEN, 331
 - circular double stranded DNA, 331
 - complex I, 43
 - clinical conditions, 246
 - dysfunction, 249–250
 - flavin mononucleotide (FMN), 246
 - in aerobic cells, 246
 - Krebs cycle, 246
 - mammalian enzyme, 246
 - nitrogen species, 247
 - ONOO⁻, 250–252
 - reversible reaction, 246
 - mitochondrial DNA (mtDNA)
 - copy number, 330, 335
 - homoplasmy and heteroplasmy, 417, 418
 - in lymphocytes, 328
 - lymphocytic mitochondrial function, 329
 - mitochondria-derived ROS, 330

- Mitochondrial and genomic mutations (*cont.*)
- mutations, cancer, 420
 - putative damage, 330
 - repair mechanism, 415
 - ROS production, 331
 - specific ZF nuclease, 337
 - variations, cancer progression, 419–420
- Mitochondrial dynamics
- ATP synthesis, 397–399
 - dynamín-related protein 1 (Drp1), 394
 - Mfn1 and Mfn2, 394
 - phosphatases, 401–403
 - physiologic and pathologic metabolism, 395, 396
- Mitochondrial dysfunction
- ASD symptoms in children, 336
 - autism spectrum disorders (ASD), 333–336
 - and cancer progression, 420–421
 - excitatory and inhibitory neurotransmission, 333
 - and immunity, 334–335
 - KGD diets, 335
 - PBDE concentrations, 333
 - PDH and GLUT1, 335
 - prenatal exposure, 334
 - standard Krebs cycle, 335
 - TLR ligands, 334
- Mitochondrial nitric oxide synthase (mtNOS), 32
- Mitochondrial permeability transition pore (MPT), 40
- Mitochondrial respiratory chain, 6, 28
- Mitochondrial transfer, 96
- cargo transfer, 97–101
 - connecting cells, 96
 - and filopodia, 97
 - human microvascular endothelial cells, 96
 - intercellular communication, 95
 - oxidative stress, 103–105
 - TNTs (*see* Tunneling nanotubes (TNTs))
- Mitochondrial-derived OS
- AD, development of, 366
 - augmented S-nitrosylation, 367
 - cellular and metabolic features, 367
 - neurons, 366
 - nitric oxide (\bullet NO), 366
 - OPTMs, 366
 - S-nitrosylated, 367
- Mitofusin 2 (Mfn2)
- early postnatal period, 394
 - embryonic lethality, midgestation, 394
 - ER–mitochondria tethering, 395
 - expression, 397
 - glucose homeostasis, 395
 - knockout mice, 395
 - localization, reticular and mitochondrial proteins, 399–401
 - loss-of-function, 396
 - mitochondrial fusion, 395
 - mutations, 395
- Molecular redox switches, 7
- Monge’s disease. *See* Chronic mountain sickness (CMS)
- Monocrotaline
- hepatic metabolism, 217
 - induced PAH, 217
 - irreversible PAH, 218
 - PAH monocrotaline model, 216
- Mononitrated nitroalkenes, 82
- mtDNA. *See* Mitochondrial DNA (mtDNA)
- mtNOS functional activity, 39
- Mucin-1 (MUC-1), 431
- Multiple sclerosis (MS)
- biochemical analyses, 310
 - demyelinated axons, 310–312
 - macrophages and microglia, 312–313
 - macrophages and microglia and oxidative stress amplification, 313
- Myelin, 313
- neuronal and axonal loss, 310
 - oligodendrocytes, 310
 - oxidative stress-mediated neurodegeneration, 310, 311
 - progressive disability, young people, 310
- Myelin
- oxidative phosphorylation, 313
- Myocardial ischemia, 65
- Myocardial mechanisms
- Akt phosphorylation, 267
 - cardiomyocytes, 263
 - cardioprotection phenomenon, 263
 - early and late reperfusion, 266
 - H₂O₂ mitochondrial production, 267
 - infarct size, 264
 - muscarinic receptors, 264
 - NO, role of, 264
 - non-rIPC/rIPC rats hearts, 266
 - parasympathetic vagal pathway, 265
 - phosphorylated Akt (Ser 473) expression, 265
 - ROS, 265
 - vagal efferent pathway, 267
- Myocardial stunning
- calcium homeostasis, 179
 - thioredoxin, 179
 - ventricular dysfunction, 247–248

N

- Na⁺-K⁺ pump, 197
- NADPH-oxidase isoform (NOX2), 87
- Neural pathway
 - autacoids, 260
 - vs. humoral, 263
 - neural afferent pathway, 262
 - peripheral nociception, 262
 - remote cardioprotection, 260
 - signal transductions, 262
 - TRPV receptors, 261
 - neuritic plaques (NPs)
 - description, 363
 - neuronal damage, 362
- Neurodegenerative diseases (ND), 350–352
 - Alzheimer disease (AD), 347
 - ALS, 348
 - biomarkers
 - brain, 350–352
 - diagnosis, 350
 - National Institutes of Health, 350
 - brain OS and oxidative damage, 347
 - cellular OS, 348
 - neuronal death, 346
 - Parkinson disease (PD), 347
 - systemic OS, 348–349
 - vascular cognitive impairment, 348
 - World Alzheimer's Report, 345
- Neurovascular coupling, 291–300
 - Alzheimer's Disease (AD), 300–302
 - functional and structural integrity, 289
 - functional brain imaging techniques, 290
 - glutamate, 290
 - Nitric Oxide (•NO), 299–300
 - systemic blood pressure, 290
 - vasoactive substances, 291
- Nitrated lipids, 59
- Nitric oxide (•NO), 39, 294–298
 - autoxidation reactions, 51
 - biological formation, 50–51
 - arachidonic acid, 298
 - astrocytes, 297
 - cGMP-dependent protein kinase, 292
 - cGMP production, 38
 - direct evidence
 - cerebral blood flow changes, 296–297
 - EDRF, 292
 - eNOS and iNOS, 292
 - glutamatergic transmission, 291–292
 - heart mtNOS (*see* Heart mitochondrial nitric oxide synthase)
 - indirect evidence
 - NOS knockout mice, 295–296
 - pharmacological approaches, 294–295
 - in mitochondria, 38
 - mitochondria-cytosol signaling, 40
 - mitochondrial respiration, 38–40
 - mitochondrial respiratory chain, 39
 - neuronal activity and local perfusion, 293
 - oxidative phosphorylation efficiency, 40
 - reaction with metal centers, 53
 - reactions with radical species, 52
 - regional specificities, 299
 - signaling and regulation, cardiac function, 38
 - somatosensory cortex NOS-positive interneurons, 293
 - steady-state concentrations, tissues, 39
 - unorthodox properties, 300
- Nitric oxide synthase (NOS)
 - Ca²⁺ binding, 291
 - immunoreactivity, 295
 - isoforms, 50, 51, 60, 67
 - knockout mice, 295
 - local metabolic/redox status, 299
 - NH₂-terminal protein variants, 295
 - pseudo-quantitative analysis, 299
 - uncoupling, 50
- Nitroalkenes, 85, 86, 88
- Nitro-arachidonic acid (NO₂-AA), 59
 - ANG II-mediated kidney injury, 88–89
 - anti-inflammatory actions, 86–88
 - Erk2 phosphorylation, thrombin-activated platelets, 84
 - formation, 80, 81
 - isomers, 82
 - lipid metabolizing enzymes, 83, 85
 - modulatory responses, vascular cells, 85
 - neuroprotection, Nrf2 activation, 89–90
 - PGHS-1 activity, 83
 - platelet activation, 84
 - platelet aggregation, 83
 - synthesis and purification, 82
 - vasorelaxing and •NO releasing properties, 84–86
- Nitro-fatty acid (NO₂-FA), 79, 80
- Nitrogen crises, 21
- Nitro-hydroxyarachidonate (NO₂(OH)AA), 80
- Nitroxidative damage
 - neurodegenerative diseases, 66
 - DNA bases, 66
 - peroxynitrite induced, 59
- Nitroxidative damage prevention
 - antioxidant inducers, 70
 - catalytic antioxidants, 69
 - direct antioxidants, 68–69
 - ONOO⁻ formation and steady state level, 67, 68

- Nitroxidative stress
 cardiovascular diseases development, 65
 inflammatory injury, 64
 neurodegenerative diseases, 66
 pathological condition, 61–62
- nNOS. *See* Nitric oxide synthase (nNOS)
- NO₂-arachidonic acid. *See* Nitro-arachidonic acid (NO₂-AA)
- O**
- Oligodendrocytes
 susceptibility to OS, 314–315
- Oligodendroglial precursor cell
 corpus callosum remyelination, 315
 hypomyelination, 315
 immature markers, 316
 and pre-OLs, 316
- Origin of mitochondria
 alpha-proteobacteria, 17
 endosymbiosis, 18, 19
- Oxidative phosphorylation (OXPHOS), 329
- Oxidative stress (OS), 131–136, 138, 195, 203–207, 219, 220, 309, 315, 376, 410
 and aging, 148
 angiotensin II (*see* Angiotensin (Ang))
 atherosclerotic cardiovascular disease, 199
 Ca²⁺ levels, 132
 cancer (*see* Cancer)
 cardiomyopathy and heart failure, 150–153
 cellular, 346
 cuprizone-induced demyelination, 314–315
 definition, forms and classification, 4–6, 29, 148, 194
 DNA alterations, 134–135
 endogenous antioxidants, 136, 138
 experimental determination, cells and tissues, 32
 extracellular SOD overexpression, 220
 free radical reactions, 30
 GSH/GSSG redox balance, 30
 hydrogen peroxide, 6
 lipid alterations, 133
 lipid peroxidation, post-ischemic reperfusion
 endogenous antioxidants, 206
 GSH concentration, 203
 mitochondrial injury score, biopsies, 207
 myocardial biopsies, 206
 myocyte ultrastructure, 206
 patient characteristics, 204
 preischemic vs. reperfusion biopsies, 205
 prototypical biopsies, 207
 radionuclide angiography data, 204
 subcellular distribution, 206
 TBARS concentration, 204, 205
 transcardiac glutathione release, 205
 MCT-treated rats, 220
 metabolic syndrome (MetS), 364–366
 mitochondria, 104, 131, 132
 mitochondrial transfer, TNTs, 104–105
 molecular redox switches, 7
 molecular signaling pathways, 135–136
 multiple sclerosis (MS), 310, 311
 multi-subunit complexes, 362
 neurovascular coupling, 301–302
 oligodendroglial precursor cell (OPC), 315
 premature cell death, 150
 prooxidants, 4
 protein alterations, 133–134
 redox medicine, 7
 ROS levels, 219, 362
 superoxide radical (O₂⁻), 148, 219
 sympathetic tone, 149–150
 systemic, 346–347
 transcardiac release, lipid peroxides, 205
 uncontrolled, 362
 white matter injury (WMI), 315–316
- Oxidative stress macromolecular damage, 194
- OXPHOS. *See* Oxidative phosphorylation (OXPHOS)
- Oxygen, 24
 mitochondrial production, 24–27
 partial reduction, 24, 29, 31
 ROS (*see* Reactive oxygen species (ROS))
- Oxygen, geological history
 atmospheric oxygen, 20
 build-up, earth's atmosphere, 20
 cambrian period, 20
 carboniferous period, 20
 photosynthetic organisms, 19
 snowball glaciations, 21
- P**
- Paired helical filaments, 363
- Pancreas
 cola drink consumption, 382, 383
 insulin secretion, 381
 α- and β-cells in pancreatic islets, 382
- Parkinson disease (PD)
- Partial reduction, O₂
 hydrogen peroxide, 31
- Particulate matter (PM)
 adverse health effects, 277
 air pollutants, 276
 air pollution exposure, 275

- cardiac effects, 278–279
 - on cardiac tissue, 281, 282
 - nanoparticles, 277
 - outdoor air pollution-related premature deaths, 276
 - pulmonary inflammation, 277, 278
 - respiratory diseases and lung cancer, 276 (see also Systemic inflammation)
 - thoracic particles, fine and ultrafine groups, 277
 - Pathology molecular mechanisms
 - mitochondrial function, cell physiology, 27–28
 - O₂⁻ and H₂O₂ mitochondrial production, 24–27
 - partial reduction of oxygen, 31–32
 - Permian–Triassic extinction event, 16
 - Peroxiporins, 6
 - Peroxynitrite (ONOO⁻)
 - apoptosis and necrosis, 63
 - biological formation, 53
 - DNA, 58
 - fates, 53–54
 - inflammation and immune responses, 64
 - lipids, 57–60
 - mitochondrial dysfunction, 60–62
 - mitochondrial reductants, 247
 - mtNOS, 250
 - nitroxidative damage to biomolecules, 59
 - nucleophilic addition to carbon dioxide, 54
 - O₂⁻ and NO, 250–252
 - scavengers, 68
 - thiol groups, 54, 55
 - tyrosine residues, 55–58
 - Phospholipid peroxidation, 27, 32
 - Physical exercise, 8
 - Poly(ADP-ribose) polymerase-1 (PARP-1), 63
 - Polybrominated diphenyl ethers (PBDEs), 332, 333
 - Polyunsaturated fatty acids (PUFAs), 80, 83, 90
 - Prooxidants
 - description, 4
 - Prostaglandin endoperoxide H synthase (PGHS), 83, 84, 88
 - Protein denitrosylation, 169–171
 - Protein disulfide isomerase (PDI)
 - balloon overdistension, 238
 - constrictive/expansion remodeling, 237, 239
 - ER stress, 236
 - injury-related thrombosis, 236
 - nitric oxide bioavailability, 237
 - oxidant generators and antioxidants, 235
 - thioredoxin superfamily protein, 235
 - VSCM migration, 236
 - Protein oxidation, 32
 - Protein S-nitrosylation
 - biological functions, 165
 - regulation, 166
 - S-nitrosothiols, formation and reduction, 164–165
 - SNO-reduction, 165
 - Protein trans-nitrosylation
 - apoptosis, 168
 - Cys73 of Trx1, 168
 - peroxiredoxin-1 (Prx1), 169
 - Trx1, 168
 - Trx1 C69S mutant, 168
 - Trx1-Cys73-SNO, 168
 - Protein tyrosine phosphatases (PTPs), 414
 - dephosphorylation, 401
 - SH2 containing PTP (SHP2), 401
 - tyrosine phosphorylation, 401
 - pulmonary arterial hypertension (PAH), 220, 221
 - classification, 214
 - epidemiology, 214–216
 - MCT action mechanism, 217, 218
 - monocrotaline (MCT) model, 216
 - oxidative stress, 219–220
 - survival, 216
 - therapeutic interventions
 - endothelin receptor antagonists, 220
 - exercise training, 221
 - flavonoids, 221
 - hormesis, 221
 - phosphodiesterase-5 inhibitors, 220
 - Pulmonary hypertension (PH), 216–219
 - classification, 215
 - description, 213
 - models
 - monocrotaline action mechanism, 217–219
 - PH monocrotaline model, 216
 - pulmonary inflammation
 - antioxidants, 278
 - cultured human alveolar macrophages, 277
 - direct generation, ROS, 278
 - inflammatory lung diseases, 277
 - neutrophil recruitment, 277
 - oxidative stress, 278
- Q**
- Q-SYMBIO clinical trial, 157

R

- Reactive nitrogen species (RNS), 50
 atherosclerosis development, 65
 cardiovascular diseases, 65
 exacerbation process, 64
 lipid radicals, 58
 neuronal death and protein tyrosine nitration, 66
 nitric oxide (*see* Nitric oxide (●NO))
 nitroxidative damage, 60
 peroxynitrite (*see* Peroxynitrite (ONOO⁻))
- Reactive oxygen species (ROS), 8
 angiotensin II, 195
 apoptosis, 412
 atherogenesis, 380
 cardiac contractility, 194
 cell proliferation and survival, 194
 cellular responses, 414–416
 DNA damage, 413
 DNA replication, 413
 HIF activation, 411
 induced renal cell carcinoma, 412
 Losartan, 195
 luminol chemiluminescence, 24
 steady states and half lives, 28–29
 testis, 399
 tumor development, 410
- Redox code, 5
 Redox homeostasis, 5
 Redox medicine
 nutrition, 7
 physical exercise, 8
- Redox process
 collagen extracellular matrix, 230
 endothelium and nitric oxide identification, 230
 glutathione peroxidase (Gpx1), 231
latu sensu, 229
 Nox NADPH-oxidases, 230
 restenosis post-balloon angioplasty, 231
 ROS production, 230
strictu sensu remodeling, 229
- Redox signaling
 hydrogen peroxide, 6
- Remote ischemic preconditioning (rIPC), 260–262
 ischemic heart disease, 260
 humoral (*see* Humoral pathway)
 mechanisms, 260, 261
 neural (*see* Neural pathway)
 in organs and tissues, 260
 ROS, 267, 268, 270
 renin-angiotensin system (RAS)
 angiotensin, 196
 Ca²⁺ transport, 197

- immune cells and inflammation, 197–198
 insulin, 196, 197
 ischemia/reperfusion (I/R) injury, 195
 melatonin, 199
 myocardial I/R damage, 195
 Na⁺-K⁺ pump, 197
 vitamin E, 198–199
- Reperfusion. *See* Ischemia/reperfusion (I/R) injury
- Reperfusion injury salvage kinase (RISK), 196
- Residual Oil Fly Ash (ROFA), 280
- Response Evaluation Criteria in Solid Tumours (RECIST), 433
- Reversible glutathionylation, 197
- Rheumatoid arthritis, 64
- ROFA. *See* Residual Oil Fly Ash (ROFA)
- ROS. *See* Reactive oxygen species (ROS)

S

- Selenoproteome, 7
- Semaphorin 3A (Sema3A), 318
- Sepsis, 66
- Shear stress-induced remodeling
 apolipoprotein E deficiency, 233
 cellular regulators, 231
 endothelium, 232
 eNOS mRNA, 232
 flow-dependent remodeling, 233
 laminar shear-associated eNOS activation, 232
 multiple Nox isoforms, 233
 Nox NADPH oxidases, 232
 proatherogenic, 232
 redox-related responses, 232
 transcription factor Nrf2, 233
- Singlet oxygen, 32
- S-Nitrosothiol formation
 oxygen-mediated pathway, 164
 transition-metal ion mediated pathway, 164
 trans-nitrosylation, 164
- Solid tumors, 434, 436
- Soluble guanylate cyclase vasorelaxation, 85
- Spin traps agents, 68
- Stable isotope labeling by amino acids in cell culture, 170
- Steady states
 ROS, 28–29
- Steroidogenesis
 Acsl4, 394
 ATP synthesis, 397, 399
 ERK1/2 activity, 397
 phosphatases, 401–403
 PKA-mediated, 400

zone glomerulosa (ZG) cells, 392
 Steroidogenic acute regulatory protein, 393,
 398–401, 403
 Stress responses
 molecular redox switches, 7
 Stunned myocardium, 246
 Submitochondrial particles (SMP), 39
 Succinate-cytochrome *c* reductase
 (complexes II-III), 39
 Superoxide anions, 247
 Superoxide dismutase (SOD), 234–235
 Symbiosis
 definition, 17
 endosymbiosis, 18, 19
 Sympathetic tone, 149, 150
 Synucleinopathies, 316
 Systemic biomarkers
 blood, 352
 non-enzymatic antioxidant defenses,
 354, 355
 Systemic inflammation
 cellular O₂ and energetic metabolism, 280
 electrochemical H⁺ gradient, 280
 heart O₂ consumption and LVDP, 281
 oxidative phosphorylation, 280
 ROFA, 280
 TNF- α biological activity, 281
 Systemic lupus erythematosus, 64
 Systemic oxidative stress, 346–347

T

T cell response
 cancer vaccines, 431, 432
 TAC. *See* Total antioxidant capacity (TAC)
 Tau and oxidative stress, 363
 Tempol, 68
The free radical theory of aging, 33
 The John Radcliffe diet, 336
 Thiol peroxidases, redox regulation, 7
 Thioredoxin (Trx), 179–182
 aging, 178
 aging hearts, 184–186
 cellular defense, 177
 ischemic preconditioning and
 postconditioning, 183, 184
 myocardial infarction, 181
 over-expression, mice, 178
 stunned myocardium
 calcium (Ca⁺⁺) homeostasis, 179
 “post-ischemic systolic
 dysfunction”, 179
 TXNIP deficiency, 179
 ventricular dysfunction behavior,
 180–182

Thioredoxin reductase isoenzymes, 416
 Thioredoxin1 (Trx1)
 protein denitrosylation, 169–171
 protein trans-nitrosylation regulation, 169
 S-nitrosylation, 166, 167, 171
 SNO-Trx1, 167
 TNTs. *See* Tunneling nanotubes (TNTs)
 α -Tocopherol (vitamin E), 198–199
 Toll-like receptor (TLR) ligands, 334
 Total antioxidant capacity (TAC), 8
 Transient receptor potential vanilloid
 (TRPV) receptors, 261
Trans-nitroalkanes, 82
Trans-nitrosylation
 SNO-Cys62, 167
 Trx1 mediated, 168, 169
 TRPV. *See* Transient receptor potential
 vanilloid (TRPV) receptors
 Trx1. *See* Thioredoxin1 (Trx1)
 Tumor immunology, 426–429, 433, 434
 adoptive T cell therapy, 435–436
 anti-tumor response
 cancer immunoediting hypothesis, 429
 components, 426–428
 tumor antigen specific T cells, 429
 checkpoint blockade, 432–435
 cytokines and vaccines, 430–432
 immune check points
 CTLA-4, 433
 PD-1, 433
 PD-1 inhibition, 434
 Tumor-infiltrating lymphocytes (TILs), 435
 Tunneling nanotubes (TNTs)
 cancer, 102, 103
 cell dislodgement, 97
 cell-cell communication and cargo
 transfer, 98–99
 cell-to-cell communication, 97
 de novo formation, 97
 formation and stabilization, 97
 immune cells, 102
 mediated cargo transfer, 97–101
 microtubules, 97
 nerve tissue cells, 102
 stem cells, 100, 101

V

Vascular dementia, 348
 Vascular remodeling, 229–231, 235–238
 advanced fibrotic plaques, 229
 atherosclerosis, 229
 definition, 228
 expansive/constrictive, 228
 interventional therapeutic procedures, 228

- Vascular remodeling (*cont.*)
neointima formation, 228
Protein disulfide isomerase (PDI), 235–238
redox process (*see* Redox process)
shear stress, 229
shear stress-induced remodeling, 231–234
- Vasorelaxation, NO₂-AA, 85, 86
- Viral and bacterial infections, 7–8
- Volatile organic compounds (VOCs), 276
- W**
- Warburg effect, 410, 421
- White matter injury
brain injury, 315
neonatal rat models, 315
- X**
- Xenobiotics, 414